2015
1.Lorenzo MJ, Moret I, Sarria B, Cases E, Cortijo J, Méndez R, Molina J, GimenoA, Menéndez R. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015 Feb 7;16(1):15. doi: 10.1186/s12931-015-0165-y. PMID: 25849726; PMCID: PMC4328072.
2.Milara J, Outeda-Macias M, Aumente-Rubio MD, Más-Serrano P, Aldaz A, Calvo MV, García-Simón MS, Martin-Barbero M, Padullés-Zamora N, Schoenenberger JA, Saavedra-Aldrich M, Tévar-Alfonso E, Saval A, Pastor-Clerigues A, García M, Margusino-Framiñan L, Montero-Alvarez JL, Merino E, Herrero JI, Beunza M,Conesa-Zamora P, Gimenez-Manzorro A, Comas-Sugrañes D, Cano-Marron M, Jiménez- Mutiloa E, Díaz-Ruíz P, Cortijo J. PEG-Interferon-α ribavirin-induced HCV viralclearance: a pharmacogenetic multicenter Spanish study. Farm Hosp. 2015 Jan
1;39(1):29-43. doi: 10.7399/fh.2015.39.1.8547. PMID: 25680433.
3. Milara J, Morcillo E, Monleon D, Tenor H, Cortijo J. Roflumilast Prevents the
Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model. PLoS One. 2015 Jul 20;10(7):e0133453. doi: 10.1371/journal.pone.0133453. PMID: 26192616; PMCID: PMC4507994.
4. Serrano G, Almudéver P, Serrano JM, Milara J, Torrens A, Expósito I, CortijoJ. Phosphatidylcholine liposomes as carriers to improve topical ascorbic acid treatment of skin disorders. Clin Cosmet Investig Dermatol. 2015 Dec 17;8:591-9. doi: 10.2147/CCID.S90781. PMID: 26719718; PMCID: PMC4687614.
5. Serrano G, Almudéver P, Serrano JM, Cortijo J, Faus C, Reyes M, Expósito I,
Torrens A, Millán F. Microneedling dilates the follicular infundibulum and
increases transfollicular absorption of liposomal sepia melanin. Clin Cosmet
Investig Dermatol. 2015 Jun 26;8:313-8. doi: 10.2147/CCID.S77228. PMID:
26170707; PMCID: PMC4489818.
6. Milara J, Morell A, Ballester B, Sanz C, Freire J, Qian X, Alonso-Garcia M,
Morcillo E, Cortijo J. Roflumilast improves corticosteroid resistance COPD
bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir
Res. 2015 Feb 5;16(1):12. doi: 10.1186/s12931-015-0179-5. PMID: 25652132; PMCID: PMC4335416.
7. Fabregat-Andres O, Paredes F, Monsalve M, Milara J, Ridocci-Soriano F,
Gonzalez-Hervas S, Mena A, Facila L, Hornero F, Morell S, Martinez-Leon J,
Cortijo J. mRNA PGC-1α levels in blood samples reliably correlates with its
myocardial expression: study in patients undergoing cardiac surgery. Anatol J Cardiol. 2016 Aug;16(8):622-629. doi: 10.5152/AnatolJCardiol.2015.6466. Epub 2015 Nov 26. PMID: 27004709; PMCID: PMC5368522.
8. Milara J, Peiró T, Serrano A, Artigues E, Aparicio J, Tenor H, Sanz C,
Cortijo J. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit
Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-
differentiated Human Bronchial Epithelial Cells in vitro. COPD. 2015
Jun;12(3):320-31. doi: 10.3109/15412555.2014.948995. Epub 2014 Sep 10. PMID: 25207459.
9. Fabregat-Andres O, Paredes F, Monsalve M, Milara J, Ridocci-Soriano F,
Gonzalez-Hervas S, Mena A, Facila L, Hornero F, Morell S, Martinez-Leon J,
Cortijo J. mRNA PGC-1α levels in blood samples reliably correlates with its
myocardial expression: study in patients undergoing cardiac surgery. Anatol J Cardiol. 2016 Aug;16(8):622-629. doi: 10.5152/AnatolJCardiol.2015.6466. Epub 2015 Nov 26. PMID: 27004709; PMCID: PMC5368522.
10. Milara J, Peiró T, Serrano A, Artigues E, Aparicio J, Tenor H, Sanz C,
Cortijo J. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit
Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-
differentiated Human Bronchial Epithelial Cells in vitro. COPD. 2015
Jun;12(3):320-31. doi: 10.3109/15412555.2014.948995. Epub 2014 Sep 10. PMID: 25207459.
2016
1. Ortiz JL, Ortiz A, Milara J, Armengot M, Sanz C, Compañ D, Morcillo E,
Cortijo J. Evaluation of Mucociliary Clearance by Three Dimension Micro-CT-SPECTin Guinea Pig: Role of Bitter Taste Agonists. PLoS One. 2016 Oct
10;11(10):e0164399. doi: 10.1371/journal.pone.0164399. PMID: 27723827; PMCID:PMC5056690.
2.Milara J, Escrivá J, Ortiz JL, Juan G, Artigues E, Morcillo E, Cortijo J.
Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonaryhypertension: an ex vivo/in vitro study. Eur Respir J. 2016 Jun;47(6):1737-49.doi: 10.1183/13993003.01259-2015. Epub 2016 Mar 23. PMID: 27009174.
3. Morales-Cano D, Moreno L, Barreira B, Briones AM, Pandolfi R, Moral-Sanz J,Callejo M, Mondejar-Parreño G, Cortijo J, Salaices M, Duarte J, Perez-VizcainoF, Cogolludo A. Activation of PPARβ/δ prevents hyperglycaemia-induced impairmentof Kv7 channels and cAMP-mediated relaxation in rat coronary arteries. Clin Sci(Lond). 2016 Oct 1;130(20):1823-36. doi: 10.1042/CS20160141. Epub 2016 Jul 13.PMID: 27413020.
4. Fabregat G, García-de-la-Asunción J, Sarriá B, Mata M, Cortijo J, de Andrés
J, Gallego L, Belda FJ. Expression of aquaporins 1 and 5 in a model of
ventilator-induced lung injury and its relation to tidal volume. Exp Physiol.
2016 Nov 1;101(11):1418-1431. doi: 10.1113/EP085729. Epub 2016 Sep 27. PMID:27424549.
5. Pastor-Clerigues A, Serrano A, Milara J, Marti-Bonmati E, Lopez-Perez FJ,
Garcia-Montanes S, Sanfeliu J, Saval-Victoria AC, Cortijo J. Evaluation of the
Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations byBovine Corneal Opacity and Permeability Test. Curr Eye Res. 2016
Jul;41(7):890-6. doi: 10.3109/02713683.2015.1082187. Epub 2015 Nov 10. PMID:26554729.
6. Fabregat-Andres O, Paredes F, Monsalve M, Milara J, Ridocci-Soriano F,
Gonzalez-Hervas S, Mena A, Facila L, Hornero F, Morell S, Martinez-Leon J,
Cortijo J. mRNA PGC-1α levels in blood samples reliably correlates with its
myocardial expression: study in patients undergoing cardiac surgery. Anatol J Cardiol. 2016 Aug;16(8):622-629. doi: 10.5152/AnatolJCardiol.2015.6466. Epub 2015 Nov 26. PMID: 27004709; PMCID: PMC5368522.
7. Fabregat-Andrés Ó, Estornell-Erill J, Ridocci-Soriano F, Pérez-Boscá JL,
García-González P, Payá-Serrano R, Morell S, Cortijo J. Prognostic Value of
Pulmonary Vascular Resistance by Magnetic Resonance in Systolic Heart Failure.Arq Bras Cardiol. 2016 Mar;106(3):226-35. doi: 10.5935/abc.20160020. Epub 2016Feb 2. PMID: 26840055; PMCID: PMC4811278.
8. Milara J, Cervera A, de Diego A, Sanz C, Juan G, Gavaldà A, Miralpeix M,
Morcillo E, Cortijo J. Non-neuronal cholinergic system contributes to
corticosteroid resistance in chronic obstructive pulmonary disease patients.
Respir Res. 2016 Nov 8;17(1):145. doi: 10.1186/s12931-016-0467-8. PMID:
27825347; PMCID: PMC5101693.
9. González-Sanz R, Mata M, Bermejo-Martín J, Álvarez A, Cortijo J, Melero JA,Martínez I. ISG15 Is Upregulated in Respiratory Syncytial Virus Infection andReduces Virus Growth through Protein ISGylation. J Virol. 2016 Jan
13;90(7):3428-38. doi: 10.1128/JVI.02695-15. PMID: 26763998; PMCID: PMC4794669.
2017
1. Contreras S, Milara J, Morcillo E, Cortijo J. Selective Inhibition of
Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases:Current and Future Evidences. Curr Pharm Des. 2017;23(14):2073-2083. doi:10.2174/1381612823666170214105651. PMID: 28201975.
2. Aparici M, Carcasona C, Ramos I, Montero JL, Ortiz JL, Cortijo J, Puig C,
Vilella D, Doe C, Gavaldà A, Miralpeix M. Pharmacological preclinical
characterization of LAS190792, a novel inhaled bifunctional muscarinic receptorantagonist /β<sub>2</sub>-adrenoceptor agonist (MABA) molecule. Pulm PharmacolTher. 2017 Oct;46:1-10. doi: 10.1016/j.pupt.2017.07.003. Epub 2017 Jul 17. PMID:28729041.
3. Milara J, Morell A, Ballester B, Armengot M, Morcillo E, Cortijo J. MUC4
impairs the anti-inflammatory effects of corticosteroids in patients with
chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017
Mar;139(3):855-862.e13. doi: 10.1016/j.jaci.2016.06.064. Epub 2016 Sep 14. PMID:27639937.
4. Milara J, Morell A, Ballester B, Armengot M, Morcillo E, Cortijo J. MUC4
impairs the anti-inflammatory effects of corticosteroids in patients with
chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017
Mar;139(3):855-862.e13. doi: 10.1016/j.jaci.2016.06.064. Epub 2016 Sep 14. PMID:27639937.
2018
1: Milara J, Díaz-Platas L, Contreras S, Ribera P, Roger I, Ballester B, Montero P, Cogolludo Á, Morcillo E, Cortijo J. MUC1 deficiency mediates corticosteroidresistance in chronic obstructive pulmonary disease. Respir Res. 2018 Nov20;19(1):226. doi: 10.1186/s12931-018-0927-4. PubMed PMID: 30458870; PubMedCentral PMCID: PMC6247701.
2: Milara J, Morell A, de Diego A, Artigues E, Morcillo E, Cortijo J. Mucin 1deficiency mediates corticosteroid insensitivity in asthma. Allergy. 2018 Jul 6. doi: 10.1111/all.13546. [Epub ahead of print] PubMed PMID: 29978485
3: Milara J, Ballester B, Morell A, Ortiz JL, Escrivá J, Fernández E,Perez-Vizcaino F, Cogolludo A, Pastor E, Artigues E, Morcillo E, Cortijo J. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension inidiopathic pulmonary fibrosis: an experimental study. Thorax. 2018
Jun;73(6):519-529. doi: 10.1136/thoraxjnl-2017-210728. Epub 2018 Feb 10. PubMedPMID: 29440315.
4: Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P, Escrivá J,Lloris JM, Molina-Molina M, Morcillo E, Cortijo J. The JAK2 pathway isactivated in idiopathic pulmonary fibrosis. Respir Res. 2018 Feb 6;19(1):24. doi:10.1186/s12931-018-0728-9. PubMed PMID: 29409529; PubMed Central PMCID:PMC5801676.
5: Chamorro V, Morales-Cano D, Milara J, Barreira B, Moreno L, Callejo M,Mondejar-Parreño G, Esquivel-Ruiz S, Cortijo J, Cogolludo Á, Barberá JA,Perez-Vizcaino F. Riociguat versus sildenafil on hypoxic pulmonaryvasoconstriction and ventilation/perfusion matching. PLoS One. 2018 Jan24;13(1):e0191239. doi: 10.1371/journal.pone.0191239. eCollection 2018. PubMedPMID: 29364918; PubMed Central PMCID: PMC5783366.
2019
1: Bisserier M, Milara J, Abdeldjebbar Y, Gubara S, Jones C, Bueno-Beti C, Chepurko E, Kohlbrenner E, Katz MG, Tarzami S, Cortijo J, Leopold J, Hajjar RJ, Sassi Y, Hadri L. AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis. Mol Ther. 2019 Dec 6. pii: S1525-0016(19)30553-2. doi: 10.1016/j.ymthe.2019.11.027. [Epub ahead of print] PubMed PMID: 31879190.
2: Milara J, Ballester B, Montero P, Escriva J, Artigues E, Alós M, Pastor-Clerigues A, Morcillo E, Cortijo J. MUC1 intracellular bioactivation mediates lung fibrosis. Thorax. 2019 Dec 4. pii: thoraxjnl-2018-212735. doi: 10.1136/thoraxjnl-2018-212735. [Epub ahead of print] PubMed PMID: 31801904.
3: Ballester B, Milara J, Cortijo J. Mucins as a New Frontier in Pulmonary Fibrosis. J Clin Med. 2019 Sep 11;8(9). pii: E1447. doi: 10.3390/jcm8091447. Review. PubMed PMID: 31514468; PubMed Central PMCID: PMC6780288.
4: Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, Milara J, Marti-Bonmati E, Trigo-Vicente C, Alós-Almiñana M, Cortijo J. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a
cost-effectiveness analysis. J Comp Eff Res. 2019 Aug;8(11):853-863. doi: 10.2217/cer-2019-0029. Epub 2019 Sep 3. PubMed PMID: 31478399.
5: Aparici M, Carcasona C, Ramos I, Montero JL, Otal R, Ortiz JL, Cortijo J, Puig C, Vilella D, De Alba J, Doe C, Gavaldà A, Miralpeix M. Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M(3) Receptor Antagonist/β (2)-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile. J Pharmacol Exp Ther. 2019 Jul;370(1):127-136. doi: 10.1124/jpet.118.255620. Epub 2019 May 13. PubMed PMID: 31085697.
6: Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int J Mol Sci. 2019 Jan 30;20(3). pii: E593. doi: 10.3390/ijms20030593. Review. PubMed PMID: 30704051; PubMed Central PMCID: PMC6387034.
7: Milara J, Contreras S, de Diego A, Calbet M, Aparici M, Morcillo E, Miralpeix M, Cortijo J. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients. PLoS One. 2019 Jan 4;14(1):e0210188. doi: 10.1371/journal.pone.0210188. eCollection 2019. PubMed PMID: 30608978; PubMed Central PMCID: PMC6319735.
8: Parrilla E, Armengot M, Mata M, Carda C, Cortijo J, Moratal D, Ginestar D, Hueso JL, Riera J. A Ciliary Motility Index for Activity Measurement in Cell Cultures With Respiratory Syncytial Virus. Am J Rhinol Allergy. 2019 Mar;33(2):121-128. doi: 10.1177/1945892418811324. Epub 2018 Nov 20. PubMed PMID: 30457015.
9: Milara J, Morell A, de Diego A, Artigues E, Morcillo E, Cortijo J. Mucin 1 deficiency mediates corticosteroid insensitivity in asthma. Allergy. 2019 Jan;74(1):111-121. doi: 10.1111/all.13546. Epub 2018 Oct 2. PubMed PMID:29978485.
2020
1: Milara J, Ballester B, Montero P, Escriva J, Artigues E, Alós M, Pastor-Clerigues A, Morcillo E, Cortijo J. MUC1 intracellular bioactivation mediateslung fibrosis. Thorax. 2020 Feb;75(2):132-142. doi:10.1136/thoraxjnl-2018-212735. Epub 2019 Dec 4. PMID: 31801904.
2: Bisserier M, Milara J, Abdeldjebbar Y, Gubara S, Jones C, Bueno-Beti C,Chepurko E, Kohlbrenner E, Katz MG, Tarzami S, Cortijo J, Leopold J, Hajjar RJ,Sassi Y, Hadri L. AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis byBlocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis. Mol Ther. 2020Feb 5;28(2):394-410. doi: 10.1016/j.ymthe.2019.11.027. Epub 2019 Dec 6. PMID:31879190; PMCID: PMC7001085.
3: Ballester B, Milara J, Cortijo J. Pirfenidone anti-fibrotic effects arepartially mediated by the inhibition of MUC1 bioactivation. Oncotarget. 2020 Apr14;11(15):1306-1320. doi: 10.18632/oncotarget.27526. PMID: 32341751; PMCID:PMC7170494.
4: Milara J, Ballester B, Safont MJ, Artigues E, Escrivá J, Morcillo E, CortijoJ. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates withtransforming growth factor β inducing fibrotic responses. Mucosal Immunol. 2020Sep 4. doi: 10.1038/s41385-020-00343-w. Epub ahead of print. PMID: 32887938.
2021
1: Roger I, Milara J, Belhadj N, Cortijo J. Senescence Alterations in PulmonaryHypertension. Cells. 2021 Dec 8;10(12):3456. doi: 10.3390/cells10123456. PMID:34943963; PMCID: PMC8700581.
2: Ballester B, Milara J, Cortijo J. The role of mucin 1 in respiratorydiseases. Eur Respir Rev. 2021 Feb 2;30(159):200149. doi:10.1183/16000617.0149-2020. PMID: 33536260.
3: Bayarri MA, Milara J, Estornut C, Cortijo J. Nitric Oxide System andBronchial Epithelium: More Than a Barrier. Front Physiol. 2021 Jun 30;12:687381.doi: 10.3389/fphys.2021.687381. PMID: 34276407; PMCID: PMC8279772.
4: Morell A, Milara J, Gozalbes L, Gavaldà A, Tarrasón G, Godessart N, Marín S,Navalón P, Cortijo J. β2-adrenoreceptors control human skin microvascularreactivity. Eur J Dermatol. 2021 Jun 1;31(3):326-334. doi:10.1684/ejd.2021.4068. PMID: 34309518.
5: Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in InterstitialLung Diseases; Molecular and Cellular Mechanisms. Int J Mol Sci. 2021 Jun9;22(12):6211. doi: 10.3390/ijms22126211. PMID: 34207510; PMCID: PMC8226626.
6: Roger I, Milara J, Montero P, Cortijo J. The Role of JAK/STAT MolecularPathway in Vascular Remodeling Associated with Pulmonary Hypertension. Int J MolSci. 2021 May 7;22(9):4980. doi: 10.3390/ijms22094980. PMID: 34067108; PMCID:PMC8124199.
7: Milara J, Ballester B, Safont MJ, Artigues E, Escrivá J, Morcillo E, CortijoJ. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates withtransforming growth factor β inducing fibrotic responses. Mucosal Immunol. 2021Mar;14(2):377-388. doi: 10.1038/s41385-020-00343-w. Epub 2020 Sep 4. PMID:32887938.
8: Ballester B, Milara J, Montero P, Cortijo J. MUC16 Is Overexpressed inIdiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated byTransforming Growth Factor-β1 Canonical Pathway. Int J Mol Sci. 2021 Jun17;22(12):6502. doi: 10.3390/ijms22126502. PMID: 34204432; PMCID: PMC8235375.
9: Reula A, Pitarch-Fabregat J, Milara J, Cortijo J, Mata-Roig M, Milian L,Armengot M. High-Speed Video Microscopy for Primary Ciliary DyskinesiaDiagnosis: A Study of Ciliary Motility Variations with Time and Temperature.Diagnostics (Basel). 2021 Jul 20;11(7):1301. doi:10.3390/diagnostics11071301.PMID: 34359383; PMCID: PMC8305583.
2022
1: Estornut C, Milara J, Bayarri MA, Belhadj N, Cortijo J. Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Jan 21;12:794997. doi: 10.3389/fphar.2021.794997. PMID:
35126133; PMCID: PMC8815729.
2: Milara J, Ballester B, de Diego A, Calbet M, Ramis I, Miralpeix M, Cortijo J. The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro. Sci Rep. 2022 Mar 24;12(1):5132. doi: 10.1038/s41598-022-09241-6. PMID: 35332239; PMCID: PMC8948298.
3: Montero P, Milara J, Pérez-Leal M, Estornut C, Roger I, Pérez-Fidalgo A, Sanz C, Cortijo J. Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model. Int J Mol Sci. 2022 Jan 20;23(3):1142. doi: 10.3390/ijms23031142. PMID: 35163066; PMCID: PMC8834980.
4: Montero P, Pérez-Leal M, Pérez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer
Patients. Cancers (Basel). 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454; PMCID: PMC8909563.
5: Roger I, Montero P, García A, Milara J, Ribera P, Pérez-Fidalgo JA, Cortijo J. Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro. Pharmaceuticals (Basel). 2022 Sep 6;15(9):1111. doi: 10.3390/ph15091111. PMID: 36145332; PMCID: PMC9501359.
